MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
19.65
-0.10
-0.51%
After Hours: 19.65 0 0.00% 19:30 08/21 EDT
OPEN
19.93
PREV CLOSE
19.75
HIGH
20.28
LOW
19.25
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
12.99
MARKET CAP
1.75B
P/E (TTM)
-7.7924
1D
5D
1M
3M
1Y
5Y
1D
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
TipRanks · 3h ago
Syndax Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 21h ago
Syndax Pharmaceuticals Price Target Cut to $33.00/Share From $37.00 by UBS
Dow Jones · 21h ago
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33
Benzinga · 21h ago
Syndax price target lowered to $33 from $37 at UBS
TipRanks · 1d ago
Loss of China Rights for Jing Zhu Da Might Change The Case For Investing In Syndax (SNDX)
Simply Wall St · 4d ago
Weekly Report: what happened at SNDX last week (0810-0814)?
Weekly Report · 5d ago
Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?
Simply Wall St · 08/15 02:28
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.